{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T02:13:07Z","timestamp":1788833587830,"version":"build-2803163510"},"reference-count":113,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T00:00:00Z","timestamp":1556582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.critrevonc.2019.04.020","type":"journal-article","created":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T12:14:24Z","timestamp":1556626464000},"page":"108-116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["The evolution and understanding of skeletal complication endpoints in clinical trials of tumors with metastasis to the bone"],"prefix":"10.1016","volume":"139","author":[{"given":"A.","family":"Hussain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.N.","family":"Graff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Halabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2019.04.020_bib0005","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/JTO.0b013e31819518fc","article-title":"Prevention and management of bone metastases in lung cancer: a review","volume":"4","author":"Al Husaini","year":"2009","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0010","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2967\/jnumed.115.160085","article-title":"Analytic validation of the automated bone scan index as an imaging biomarker to standardize quantitative changes in bone scans of patients with metastatic prostate Cancer","volume":"57","author":"Anand","year":"2016","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0015","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.juro.2016.09.117","article-title":"Multisite experience of the safety, detection rate and diagnostic performance of fluciclovine ((18)F) positron emission Tomography\/Computerized tomography imaging in the staging of biochemically recurrent prostate Cancer","volume":"197","author":"Bach-Gansmo","year":"2017","journal-title":"J. Urol."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0020","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S1470-2045(13)70539-4","article-title":"Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial","volume":"15","author":"Barrett-Lee","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0025","series-title":"Xofigo (radium-223) [prescribing information]","author":"Bayer HealthCare Pharmaceuticals Inc","year":"2018"},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0030","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group","volume":"334","author":"Berenson","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0035","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","article-title":"Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group","volume":"16","author":"Berenson","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0040","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S0022-5347(05)67149-2","article-title":"Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline","volume":"164","author":"Berruti","year":"2000","journal-title":"J. Urol."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0045","article-title":"Bone targeted therapies in advanced breast cancer","volume":"100","author":"Biskup","year":"2017","journal-title":"Swiss Med."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0050","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.critrevonc.2017.04.008","article-title":"Systematic review and meta-analysis on the proportion of patients with breast cancer who develop bone metastases","volume":"115","author":"Body","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0055","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ctrv.2017.09.008","article-title":"Early identification and intervention matters: a comprehensive review of current evidence and recommendations for the monitoring of bone health in patients with cancer","volume":"61","author":"Brodowicz","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0060","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/cncr.26313","article-title":"Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole","volume":"118","author":"Brufsky","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0065","doi-asserted-by":"crossref","first-page":"6250s","DOI":"10.1158\/1078-0432.CCR-06-0841","article-title":"High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?","volume":"12","author":"Bruland","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0070","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1053\/hp.2000.6698","article-title":"Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients","volume":"31","author":"Bubendorf","year":"2000","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0075","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1002\/1097-0142(20000615)88:12+<2989::AID-CNCR14>3.0.CO;2-Q","article-title":"The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma","volume":"88","author":"Carlin","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0080","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ijrobp.2017.09.030","article-title":"Comparing the effectiveness of combined external beam radiation and hyperthermia versus external beam radiation alone in treating patients with painful bony metastases: a phase 3 prospective, randomized, controlled trial","volume":"100","author":"Chi","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0085","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1200\/JCO.2006.09.5281","article-title":"Palliative radiotherapy trials for bone metastases: a systematic review","volume":"25","author":"Chow","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0090","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0095","doi-asserted-by":"crossref","first-page":"27s","DOI":"10.2967\/jnumed.115.157867","article-title":"Imaging bone metastases in breast Cancer: staging and response assessment","volume":"57","author":"Cook","year":"2016","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0100","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/jnci\/djg038","article-title":"A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial)","volume":"95","author":"Dearnaley","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0105","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1200\/JCO.2011.36.5791","article-title":"Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer","volume":"30","author":"Dennis","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0110","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","article-title":"Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer","volume":"26","author":"Ellis","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0115","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0120","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate Cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0125","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in Nonmetastatic, castration-resistant prostate Cancer","author":"Fizazi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0130","series-title":"Guidance for Industry Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics","author":"Food and Drug Administration","year":"2007"},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0135","series-title":"Nonmetastatic, Castration-resistant Prostate Pancer: Considerations for Metastasis-free Survival Endpoint in Clinical Trials. Guidance for Industry","author":"Food and Drug Administration","year":"2018"},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0140","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.radonc.2008.05.018","article-title":"Randomized clinical trial with two palliative radiotherapy regimens in painful bone metastases: 30 Gy in 10 fractions compared with 8 Gy in single fraction","volume":"89","author":"Foro Arnalot","year":"2008","journal-title":"Radiother. Oncol."},{"issue":"73","key":"10.1016\/j.critrevonc.2019.04.020_bib0145","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.eururo.2017.06.002","article-title":"Management of patients with advanced prostate Cancer: the report of the advanced prostate Cancer consensus conference APCCC 2017","author":"Gillessen","year":"2018","journal-title":"Eur. Urol."},{"issue":"28","key":"10.1016\/j.critrevonc.2019.04.020_bib0150","first-page":"e21","article-title":"The current role and limitations of surrogate endpoints in advanced prostate cancer","volume":"32","author":"Gomella","year":"2014","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0155","first-page":"310","article-title":"Breast Cancer, version 4.2017, NCCN clinical practice guidelines in oncology","volume":"16","author":"Gradishar","year":"2018","journal-title":"J. Compr. Canc. Netw."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0160","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1200\/JCO.2015.65.7270","article-title":"Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate Cancer","volume":"34","author":"Halabi","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0165","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4137\/CGM.S16817","article-title":"Bone disease in multiple myeloma: pathophysiology and management","volume":"7","author":"Hameed","year":"2014","journal-title":"Cancer Growth Metastasis"},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0170","first-page":"3120","article-title":"Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model","volume":"62","author":"Henriksen","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0175","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0180","first-page":"679","article-title":"Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors","volume":"22","author":"Henry","year":"2014","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0185","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2016.19425","article-title":"Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial","volume":"317","author":"Himelstein","year":"2017","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0190","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","article-title":"Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer study Group","volume":"335","author":"Hortobagyi","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0195","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.1998.16.6.2038","article-title":"Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer study Group","volume":"16","author":"Hortobagyi","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0200","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/pcan.2016.26","article-title":"Do skeletal-related events predict overall survival in men with metastatic castration-resistant prostate cancer?","volume":"19","author":"Howard","year":"2016","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0205","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1002\/cam4.914","article-title":"Risk of skeletal related events among elderly prostate cancer patients by site of metastasis at diagnosis","volume":"5","author":"Hussain","year":"2016","journal-title":"Cancer Med."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0210","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193661","article-title":"Prevalence and risk of skeletal complications and use of radiation therapy in elderly women diagnosed with metastatic breast cancer","volume":"13","author":"Hussain","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0215","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","article-title":"Enzalutamide in men with nonmetastatic, castration-resistant prostate Cancer","volume":"378","author":"Hussain","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0220","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1186\/s40064-016-2741-0","article-title":"Bone Scan Index predicts skeletal-related events in patients with metastatic breast cancer","volume":"5","author":"Idota","year":"2016","journal-title":"Springerplus"},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0225","first-page":"1765","article-title":"A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index","volume":"4","author":"Imbriaco","year":"1998","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0230","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate Cancer Not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0235","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/01.NOR.0000320543.90115.d5","article-title":"Surgical interventions for cancer patients with impending or actual pathologic fractures","volume":"27","author":"Johnson","year":"2008","journal-title":"Orthop. Nurs."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0240","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1535-6108(03)00132-6","article-title":"A multigenic program mediating breast cancer metastasis to bone","volume":"3","author":"Kang","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0245","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1586\/erm.11.44","article-title":"Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management","volume":"11","author":"Kristinsson","year":"2011","journal-title":"Expert Rev. Mol. Diagn."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0250","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/0277-5379(91)90257-E","article-title":"A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone","volume":"27","author":"Lewington","year":"1991","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0255","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/pcan.2017.4","article-title":"Impact of symptomatic skeletal events on health-care resource utilization and quality of life among patients with castration-resistant prostate cancer and bone metastases","volume":"20","author":"McKay","year":"2017","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0260","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1158\/1078-0432.CCR-17-3577","article-title":"Radium-223 dichloride in combination with vascular endothelial growth factor-targeting therapy in advanced renal cell carcinoma with bone metastases","volume":"24","author":"McKay","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0265","article-title":"Radiotherapy for the palliation of painful bone metastases","author":"McQuay","year":"2000","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0270","first-page":"1081","article-title":"Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines","volume":"10","author":"Mohler","year":"2012","journal-title":"J. Compr. Canc. Netw."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0275","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1177\/107327481702400206","article-title":"Skeletal scintigraphy","volume":"24","author":"Montilla-Soler","year":"2017","journal-title":"Cancer Control"},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0280","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1053\/j.seminoncol.2013.04.008","article-title":"Monitoring the clinical outcomes in advanced prostate cancer: what imaging modalities and other markers are reliable?","volume":"40","author":"Morris","year":"2013","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0285","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2014.55.3875","article-title":"Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results","volume":"33","author":"Morris","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0290","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis to bone: causes, consequences and therapeutic opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0295","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0167-8140(98)00011-5","article-title":"Randomized trial of single dose versus fractionated palliative radiotherapy of bone metastases","volume":"47","author":"Nielsen","year":"1998","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0300","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s10147-013-0604-z","article-title":"Phase II trial of zoledronic acid combined with androgen-deprivation therapy for treatment-naive prostate cancer with bone metastasis","volume":"19","author":"Nozawa","year":"2014","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0305","article-title":"Beyond the vicious cycle: the role of innate osteoimmunity, automimicry and tumor-inherent changes in dictating bone metastasis","author":"Owen","year":"2017","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0310","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0315","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0140-6736(05)66954-1","article-title":"Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial","volume":"366","author":"Patchell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0320","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.eururo.2013.10.055","article-title":"Visceral disease in castration-resistant prostate cancer","volume":"65","author":"Pezaro","year":"2014","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0325","first-page":"27","article-title":"Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases","volume":"3","author":"Polascik","year":"2009","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0330","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/0360-3016(93)90309-J","article-title":"Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer","volume":"25","author":"Porter","year":"1993","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0335","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1007\/s00259-016-3435-0","article-title":"Comparison of bone scintigraphy and (68)Ga-PSMA PET for skeletal staging in prostate cancer","volume":"43","author":"Pyka","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0340","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0345","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1001\/jamaoncol.2017.5808","article-title":"Radiographic progression-free survival as a clinically meaningful end point in metastatic castration-resistant prostate Cancer: the PREVAIL randomized clinical trial","volume":"4","author":"Rathkopf","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0350","first-page":"302","article-title":"Mortality and complications following stabilization of femoral metastatic lesions: a population-based study of regional variation and outcome","volume":"52","author":"Ristevski","year":"2009","journal-title":"Can. J. Surg."},{"issue":"17","key":"10.1016\/j.critrevonc.2019.04.020_bib0355","article-title":"The burden of skeletal-related events in patients with prostate cancer and bone metastasis","volume":"33","author":"Roghmann","year":"2015","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0360","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0365","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group","volume":"21","author":"Rosen","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0370","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","article-title":"Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0375","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.juro.2008.04.140","article-title":"Histopathological assessment of prostate cancer bone osteoblastic metastases","volume":"180","author":"Roudier","year":"2008","journal-title":"J. Urol."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0380","series-title":"Apollo 14 and the Lessons From Fractures","author":"Ryan","year":"2018"},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0385","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0390","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0395","doi-asserted-by":"crossref","first-page":"5465","DOI":"10.1200\/JCO.2008.18.4184","article-title":"Cancer treatment-induced bone loss in breast and prostate cancer","volume":"26","author":"Saad","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0400","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/pcan.2016.62","article-title":"Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: data from PREVAIL and AFFIRM trials","volume":"20","author":"Saad","year":"2017","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0405","doi-asserted-by":"crossref","first-page":"18670","DOI":"10.1038\/srep18670","article-title":"Natural history of non-small-Cell lung Cancer with bone metastases","volume":"5","author":"Santini","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0410","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.urology.2004.01.034","article-title":"Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer","volume":"63","author":"Sartor","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0415","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(14)70183-4","article-title":"Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial","volume":"15","author":"Sartor","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0420","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0425","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1200\/JCO.2011.35.8648","article-title":"End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice","volume":"29","author":"Scher","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0430","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate Cancer: updated recommendations from the prostate Cancer Clinical trials working group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0435","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1093\/annonc\/mdv326","article-title":"Assessment of anticancer-treatment outcome in patients with metastatic castration-resistant prostate cancer-going beyond PSA and imaging, a systematic literature review","volume":"26","author":"Schmid","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0440","article-title":"External beam radiation therapy (EBRT) for asymptomatic bone metastases in patients with solid tumors reduces the risk of skeletal-related events (SREs)","author":"Shulman","year":"2018","journal-title":"Ann. Palliat. Med."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0445","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0450","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0455","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1200\/JCO.2013.51.6500","article-title":"Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance)","volume":"32","author":"Smith","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0460","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdu519","article-title":"Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events","volume":"26","author":"Smith","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0465","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate Cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0470","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S1470-2045(18)30860-X","article-title":"Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Smith","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0475","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0480","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/nrendo.2010.227","article-title":"Bone metastasis: mechanisms and therapeutic opportunities","volume":"7","author":"Suva","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0485","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S1701-2163(16)31095-7","article-title":"Bone densitometry: applications and limitations","volume":"24","author":"Syed","year":"2002","journal-title":"J. Obstet. Gynaecol. Can."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0490","series-title":"Radium-223 Following Front-line Chemotherapy for Patients With Non-small Cell Lung Cancer and Bone Metastases","author":"Taber","year":"2018"},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0495","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.1996.14.6.1756","article-title":"Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points","volume":"14","author":"Tannock","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0500","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0505","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00256-007-0404-5","article-title":"Radiofrequency ablation of osseous metastases for the palliation of pain","volume":"37","author":"Thanos","year":"2008","journal-title":"Skeletal Radiol."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0510","doi-asserted-by":"crossref","first-page":"86","DOI":"10.4103\/0019-509X.25890","article-title":"Samarium-153 ethylenediamine tetramethylene phosphonate therapy for bone pain palliation in skeletal metastases","volume":"43","author":"Tripathi","year":"2006","journal-title":"Indian J. Cancer"},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0515","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.lungcan.2007.03.013","article-title":"Skeletal metastases in non-small cell lung cancer: a retrospective study","volume":"57","author":"Tsuya","year":"2007","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0520","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1186\/s12885-016-2947-0","article-title":"Comparing conVEntional RadioTherapy with stereotactIC body radiotherapy in patients with spinAL metastases: study protocol for an randomized controlled trial following the cohort multiple randomized controlled trial design","volume":"16","author":"van der Velden","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0525","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000030361","article-title":"Patterns of metastasis in muscle-invasive bladder cancer (pT2-4): an autopsy study on 367 patients","volume":"62","author":"Wallmeroth","year":"1999","journal-title":"Urol. Int."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0530","doi-asserted-by":"crossref","first-page":"S230","DOI":"10.1097\/01.blo.0000093849.72468.82","article-title":"Metastatic disease of the femur: surgical treatment","author":"Ward","year":"2003","journal-title":"Clin. Orthop. Relat. Res."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0535","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nrc3055","article-title":"Cancer to bone: a fatal attraction","volume":"11","author":"Weilbaecher","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0540","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/annonc\/mdi122","article-title":"The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer","volume":"16","author":"Weinfurt","year":"2005","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0545","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.bone.2010.09.008","article-title":"Skeletal complications and survival in renal cancer patients with bone metastases","volume":"48","author":"Woodward","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0550","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1200\/JCO.2017.73.9987","article-title":"Metastasis-free survival is a strong surrogate of overall survival in localized prostate Cancer","volume":"35","author":"Xie","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0555","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jbo.2017.08.004","article-title":"Increased risk of SSEs in bone-only metastatic breast cancer patients treated with zoledronic acid","volume":"8","author":"Yanae","year":"2017","journal-title":"J. Bone Oncol."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0560","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s10549-011-1475-5","article-title":"Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999-2007)","volume":"129","author":"Yong","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2019.04.020_bib0565","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/CCO.0000000000000071","article-title":"Clinical and economic burden of bone metastasis and skeletal-related events in prostate cancer","volume":"26","author":"Yong","year":"2014","journal-title":"Curr. Opin. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084281930085X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084281930085X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:29:49Z","timestamp":1760902189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104084281930085X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":113,"alternative-id":["S104084281930085X"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2019.04.020","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The evolution and understanding of skeletal complication endpoints in clinical trials of tumors with metastasis to the bone","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2019.04.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}